Date:6/27/2010

the Kaiser Permanete Division of Research; Katherine Yih, MPH, PhD, from Harvard Pilgrim HealthCare Institute and Harvard Medical School, Boston, MA; Edwin Lewis, MPH, from the Kaiser Permanente Vaccine Study Center; Martin Kulldorff, PhD, from Harvard Pilgrim Healthcare Institute; Paula Ray, MPH, from the Kaiser Permanente Vaccine Study Center; Roger Baxter, MD, from the Kaiser Permanente Vaccine Study Center; Simon Hambridge, MD, PhD, from Kaiser Permanente, Denver, Co; James Nordin, MD, MPA, from Health Partners Research Foundation, Minneapolis, MN; Allison Naleway, PhD, Kaiser Permanente, Portland, OR; Edward A. Belongia, MD, from Marshfield Clinic Research Foundation; Tracy Lieu, MD, MPH, from Harvard Pilgrim Health Care Institute; James Baggs, PhD, from the Immunization Safety Office, CDC; Eric Weintraub, MPH, from the Vaccine Safety Datalink. Funding for the study was provided by the Vaccine Safety Datalink contract with America's Health Insurance Plans, funded by the Centers for Disease Control and Prevention.

About the Kaiser Permanente Division of Research (http://www.dor.kaiser.org/)

The Kaiser Permanente Division of R
'/>"/>

SOURCE Kaiser Permanente Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. New Data Demonstrated Efficacy and Safety of Initial Combination Therapy with Welchol(R) (colesevelam HCl) and Metformin in Drug-Naive Adult Type 2 Diabetes Patients
2. Data Show OrbusNeichs Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon
3. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
4. FDA Approves New Combination Product Oral Contraceptive
5. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
6. Global Partners Join Forces to Speed Development of New TB Drug Combinations
7. FDA Announces Possible Safety Concern for HIV Drug Combination
8. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
9. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
10. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
11. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)